What question did this study set out to answer?

To evaluate the effectiveness of KRAS p.G12C inhibitors in treating metastatic colorectal cancer.

March 7, 2026

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science

Key Points

To evaluate the effectiveness of KRAS p.G12C inhibitors in treating metastatic colorectal cancer.
Conducted a systematic review of available literature
Assessed the efficacy of KRAS-G12C inhibitors
Examined the combination with anti-EGFR therapy
Compared results to historical data on chemotherapy-refractory CRC
Initial data shows promising results for KRAS-G12C inhibitors
Combination therapy with anti-EGFR enhances efficacy
Supports future frontline trials with these new treatments

Abstract

Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science

Key Points

Abstract

Cite This Study